Table 3.
Parameters | Correlation with NeH2S level | ||
---|---|---|---|
Correlation coefficient | p value | ||
Course of AR (years) | 0.174 | 0.111 | |
SAR or PAR | ~ | 0.135 | |
Persistence of AR symptoms | Months with symptoms per year a | 0.144 | 0.189 |
Weeks with symptoms per month b | −0.187 | 0.087 | |
Days with symptoms per week c | −0.158 | 0.148 | |
Severity of AR symptoms | Sleep disturbance d | −0.118 | 0.282 |
Impairment of school or work d | −0.097 | 0.378 | |
Impairment of leisure or sport d | −0.021 | 0.851 | |
Impairment of other daily activities d | −0.013 | 0.903 | |
Comorbidities | With or without asthma | ~ | 0.285 |
With or without rhinosinusitis | ~ | 0.161 | |
IgE level | Total IgE | −0.036 | 0.751 |
Phadiatop sIgE | 0.008 | 0.943 |
Abbreviations: AR, allergic rhinitis; NeH2S, nasal exhaled hydrogen sulfide; PAR, perennial allergic rhinitis; SAR, seasonal allergic rhinitis; sIgE, specific immunoglobulin E.
This parameter was divided into five levels to evaluate the correlation: 1‐less than one month, 2‐one to three months, 3‐four to six months, 4‐seven to nine months, 5‐more than ten months.
This parameter was divided into four levels to evaluate the correlation: 1‐less than one week, 2‐one to two weeks, 3‐three to four weeks, 4‐every day.
This parameter was divided into four levels to evaluate the correlation: 1‐less than one day, 2‐one to three days, 3‐four to six days, 4‐every day.
These parameters were divided into five levels to evaluate the correlation: 0‐none, 1‐mild, 2‐moderate, 3‐severe, 4‐very severe.